References
1. Driessen EMC, De Lorenzo P, Campbell M, et al. Outcome of relapsed
infant acute lymphoblastic leukemia treated on the interfant-99
protocol. Leukemia 2016;30:1184-1187.
2. Bhojwani D, Sposto R, Shah NN, et al. Inotuzumab ozogamicin in
pediatric patients with relapsed/refractory acute lymphoblastic
leukemia. Leukemia 2019;33:884-892.
3. Brivio E, Chantrain CF, Gruber TA, et al. Inotuzumab ozogamicin in
infants and young children with relapsed or refractory acute
lymphoblastic leukemia: A case series. Br J Haematol 2021;193:1172-1177.
4. Pieters R, De Lorenzo P, Ancliffe P, et al. Outcome of infants
younger than 1 year with acute lymphoblastic leukemia treated with the
interfant-06 protocol: Results from an international phase III
randomized study. J Clin Oncol 2019;37:2246-2256.
5. Jabbour EJ, Deangelo DJ, Stelljes M, Stock W, Liedtke M. Efficacy and
safety analysis by age cohort of inotuzumab ozogamicin in patients with
relapsed or refractory acute lymphoblastic leukemia enrolled in
INO-VATE. Cancer 2018;124:1722-1732.
6. Stock W, Gökbuget N, Brien SO, et al. Inotuzumab ozogamicin versus
standard therapy for acute lymphoblastic leukemia. N Engl J Med
2016;375:740-753.
7. McNeer JL, Rau RE, Gupta S, Maude SL, O’Brien MM. Cutting to the
front of the line: Immunotherapy for childhood acute lymphoblastic
leukemia. Am Soc Clin Oncol Educ B 2020;40:e132-e143.